Alzheimer's Disease Agents

Alzheimer’s disease agents are a therapeutic category of pharmaceuticals indicated to slow disease progression or manage cognitive and behavioral decline in individuals with Alzheimer’s disease and related dementias

Alzheimer’s disease agents are a therapeutic category of pharmaceuticals indicated to slow disease progression or manage cognitive and behavioral decline in individuals with Alzheimer’s disease and related dementias

Mechanistically, this class includes disease-modifying therapies, such as amyloid-beta-directed monoclonal antibodies that promote the clearance of neuropathologic plaques to attenuate functional decline, as well as symptomatic agents like cholinesterase inhibitors and NMDA receptor antagonists that regulate essential neurotransmitters like acetylcholine and glutamate to support cognition

Mechanistically, this class includes disease-modifying therapies, such as amyloid-beta-directed monoclonal antibodies that promote the clearance of neuropathologic plaques to attenuate functional decline, as well as symptomatic agents like cholinesterase inhibitors and NMDA receptor antagonists that regulate essential neurotransmitters like acetylcholine and glutamate to support cognition

Their primary therapeutic role is in managing mild cognitive impairment and mild-to-severe dementia attributable to Alzheimer’s pathology

Their primary therapeutic role is in managing mild cognitive impairment and mild-to-severe dementia attributable to Alzheimer’s pathology

Their primary therapeutic role is in managing mild cognitive impairment and mild-to-severe dementia attributable to Alzheimer’s pathology